The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Recombinant Tissue-Type Plasminogen Activator Use for Ischemic Stroke in the United States: A Doubling of Treatment Rates Over the Course of 5 Years
Open accessAbstract
Background and Purpose—: Recombinant tissue-type plasminogen activator (rtPA) is the only approved therapy for acute ischemic stroke (AIS). In 2004, 1.8% to 2.1% of AIS patients in the United States received rtPA. Given incentives from regulatory agencies and payors to increase rtPA use, we hypothesized that rtPA use in the United States would increase from 2005 to 2009. Methods—: AIS cases were defined by exclusion of hemorrhagic stroke and transient ischemic attack International Classification of Diseases 9 th revision codes (430, 431, 432, and 435) from diagnosis-related groups 14, 15, 524, and 559 discharges. Patients receiving thrombolytics were identified using International Classification of Diseases 9 th revision code 99.10 (Medicare Provider and Analysis Review and Premier databases) and pharmacy billing records (Premier). Change over time and differences between databases were tested using negative binomial regression. Results—: Within Medicare Provider and Analysis Review, thrombolytic use increased from 1.1% in 2005 to 3.4% in 2009 ( P <0.001 for trend). Within Premier, thrombolytic use increased from 1.4% in 2005 to 3.7% in 2009 for all cases ( P <0.001). Analysis of pharmacy billing records in Premier for 50-mg or 100-mg doses of rtPA showed that 3.4% of AIS cases were treated in 2009. Inclusion of patients with transient ischemic attack or hemorrhagic stroke International Classification of Diseases 9 th revision codes who received any thrombolytic as “ischemic stroke patients receiving rtPA” changed the rate of thrombolysis to 5.2%. Conclusions—: In 2009, 3.4% to 5.2% of AIS patients in the United States received thrombolytics, approximately double the rate of treatment in 2005. Rapid recognition and transport and quick treatment in the emergency department remain goals for further improving treatment rates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue Plasminogen Activator for Acute Ischemic Stroke
(1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332401 · Cited by 11,654
Heart Disease and Stroke Statistics—2010 Update: A Report From the American Heart Association
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., Ferguson, T. B., Ford, E., Furie, K., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.192667 · Cited by 5,700
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., Ferguson, T. B., Ford, E., Furie, K., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.192666 · Cited by 1,359
Kleindorfer, D., Kissela, B., Schneider, A., Woo, D., Khoury, J., Miller, R., Alwell, K., Gebel, J., Szaflarski, J., Pancioli, A., et al. (2004) · Stroke · doi:10.1161/01.str.0000109767.11426.17 · Cited by 299
Self-citationUtilization of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke
Katzan, I. L., Hammer, M. D., Hixson, E. D., Furlan, A. J., Abou-Chebl, A., & Nadzam, D. M. (2004) · Archives of Neurology · doi:10.1001/archneur.61.3.346 · Cited by 289
Prioritizing interventions to improve rates of thrombolysis for ischemic stroke
California Acute Stroke Pilot Registry (CASPR) Investigators (2005) · Neurology · doi:10.1212/01.wnl.0000151850.39648.51 · Cited by 274
Kleindorfer, D., Lindsell, C. J., Brass, L., Koroshetz, W., & Broderick, J. P. (2008) · Stroke · doi:10.1161/strokeaha.107.490375 · Cited by 274
Self-citationQureshi, A. I., Suri, M. F. K., Nasar, A., He, W., Kirmani, J. F., Divani, A. A., Prestigiacomo, C. J., & Low, R. B. (2005) · Neurosurgery · doi:10.1227/01.neu.0000175546.62088.d6 · Cited by 97
Essay: White daisies on my mind (Requiem for an Alzheimer patient)
Janson, C. G. (2005) · Neurology · doi:10.1212/01.wnl.0000173032.00531.87 · Cited by 58
Cited by
Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000485 · Cited by 12,591
Heart Disease and Stroke Statistics—2016 Update: A Report From the American Heart Association
Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., Das, S. R., de Ferranti, S., Després, J.-P., Fullerton, H. J., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000350 · Cited by 6,596
Heart Disease and Stroke Statistics—2015 Update: A Report From the American Heart Association
Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., de Ferranti, S., Després, J.-P., Fullerton, H. J., Howard, V. J., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000152 · Cited by 5,797
Heart Disease and Stroke Statistics—2014 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., et al. (2014) · Circulation · doi:10.1161/01.cir.0000441139.02102.80 · Cited by 5,215
Mitochondria as a therapeutic target for common pathologies
Murphy, M. P., & Hartley, R. C. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.174 · Cited by 827
Lackland, D. T., Roccella, E. J., Deutsch, A. F., Fornage, M., George, M. G., Howard, G., Kissela, B. M., Kittner, S. J., Lichtman, J. H., Lisabeth, L. D., et al. (2014) · Stroke · doi:10.1161/01.str.0000437068.30550.cf · Cited by 815
Demaerschalk, B. M., Kleindorfer, D. O., Adeoye, O. M., Demchuk, A. M., Fugate, J. E., Grotta, J. C., Khalessi, A. A., Levy, E. I., Palesch, Y. Y., Prabhakaran, S., et al. (2016) · Stroke · doi:10.1161/str.0000000000000086 · Cited by 670
Self-citationPrehospital Use of Magnesium Sulfate as Neuroprotection in Acute Stroke
Saver, J. L., Starkman, S., Eckstein, M., Stratton, S. J., Pratt, F. D., Hamilton, S., Conwit, R., Liebeskind, D. S., Sung, G., Kramer, I., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408827 · Cited by 407
Recent advances in the management of acute ischemic stroke
Chang, P., & Prabhakaran, S. (2017) · F1000Research · doi:10.12688/f1000research.9191.1 · Cited by 379
Schwamm, L. H., Ali, S. F., Reeves, M. J., Smith, E. E., Saver, J. L., Messe, S., Bhatt, D. L., Grau-Sepulveda, M. V., Peterson, E. D., & Fonarow, G. C. (2013) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.111.000095 · Cited by 305
Oxidative Stress and the Use of Antioxidants in Stroke
Shirley, R., Ord, E., & Work, L. (2014) · Antioxidants · doi:10.3390/antiox3030472 · Cited by 282
Mitochondria as a therapeutic target for ischemic stroke
He, Z., Ning, N., Zhou, Q., Khoshnam, S. E., & Farzaneh, M. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.11.005 · Cited by 267
Meta-analysis of preclinical studies of mesenchymal stromal cells for ischemic stroke
Vu, Q., Xie, K., Eckert, M., Zhao, W., & Cramer, S. C. (2014) · Neurology · doi:10.1212/wnl.0000000000000278 · Cited by 235
Exosomes and stem cells in degenerative disease diagnosis and therapy
Chang, Y.-H., Wu, K.-C., Harn, H.-J., Lin, S.-Z., & Ding, D.-C. (2018) · Cell Transplantation · doi:10.1177/0963689717723636 · Cited by 159
Scott, P. A., Meurer, W. J., Frederiksen, S. M., Kalbfleisch, J. D., Xu, Z., Haan, M. N., Silbergleit, R., & Morgenstern, L. B. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70311-3 · Cited by 96
Metadata
- Authors
- Adeoye, O., Hornung, R., Khatri, P., & Kleindorfer, D.
- Venue
- Stroke
- Published
- 2011-07
- Volume
- 42
- Issue
- 7
- Pages
- 1952-1955
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2128968009
- Cited by
- 474
- References
- 9
- FWCI
- 35.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.